Capital Management Associates (New York)’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Capital Management Associates (New York)’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$766K	Hold	6,000	–	–	1.27%	31
2025 Q4	$732K	Buy	+6,000	New	+$688K	1.07%	37

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Capital Management Associates (New York)'s XBI Position: Q1 2026 in Review

Capital Management Associates (New York) held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q1 2026 at 6,000 shares worth $766K. The position accounts for 1.27% of the portfolio, ranked #31.

Capital Management Associates (New York) first reported a position in XBI in Q4 2025 and has held it in 2 quarters since. 815 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Capital Management Associates (New York) held 6,000 shares of State Street SPDR S&P Biotech ETF worth $766K as of Q1 2026.
Capital Management Associates (New York) left its State Street SPDR S&P Biotech ETF share count unchanged in Q1 2026.
State Street SPDR S&P Biotech ETF made up 1.27% of Capital Management Associates (New York)'s portfolio in Q1 2026, its #31 holding.
Capital Management Associates (New York) first reported a position in State Street SPDR S&P Biotech ETF in Q4 2025 and has held it in 2 quarters since.
815 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Capital Management Associates (New York)'s 13F filing for Q1 2026, filed 4 May 2026.